| 证券代码 | ABP.O |
| 证券名称 | Abpro Corp |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | - |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | UBS Securities LLC,Wells Fargo Securities, LLC |
| 货币单位 | - |
| 公司名称 | Abpro Corporation |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 68 Cummings Park Drive, Woburn, Massachusetts, USA |
| 成立日期 | 2004-08 |
| 董事会主席 | Ian Chan |
| 公司属地 | United States 美国 |
| 公司网址 | www.abpro.com |
| 电话 | +1 (617) 225-0808 |
| 传真 | - |
| 公司简介 | Abpro Corporation is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. It is initially focused on novel antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. By leveraging its proprietary DiversImmune and MultiMab antibody discovery and engineering platforms, is are developing a pipeline of potentially best-in-class antibodies, both independently and through collaborations with global pharmaceutical and research institutions. |